Ligand Pharmaceutical (LGND) Stock
Biotech firm providing drug development technology and earning royalties. Here's the price, business snapshot, and what's worth knowing about Ligand Pharmaceutical in September 2026.
Ligand Pharmaceuticals (LGND) is a US-based biotechnology company that provides technologies and services to help other drug developers discover, develop and commercialise medicines. Instead of focusing mainly on its own drug pipeline, Ligand earns revenue through licensing, milestone payments, royalties and strategic collaborations tied to partner programmes. Its portfolio includes platform technologies such as Captisol (drug formulation) and OmniAb (antibody discovery), which can broaden the company’s exposure across therapeutic areas. With a market capitalisation of about $3.66 billion, Ligand offers a royalty-driven business model that can deliver recurring revenues, but it remains dependent on partner success, regulatory approvals and licensing activity. Investors should be aware that biotech stocks are typically volatile; past performance does not predict future returns. This is general, educational information and not personal investment advice — suitability depends on your circumstances and risk tolerance, so consider professional advice before making decisions.
Ligand Pharmaceutical (LGND) Stock Forecast
Analyst price target, next 12 months
$249.19
-15.5% vs today's $294.78
Price range over the last 12 months
Close to its 12-month high
Analysts covering Ligand Pharmaceutical have a consensus 12-month target of $249.19, below the current price of $294.78.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 23 Sep 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Ligand Pharmaceutical's stock with a target price of $249.19, indicating growth potential.
Financial Health
Ligand Pharmaceutical is performing well, showing strong profits and cash flow, with solid revenue growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Royalty Revenue Model
Recurring royalties and milestone payments can provide revenue visibility, though those streams depend on partner successes and are vulnerable to setbacks.
Proprietary Technology Platforms
Platforms such as Captisol and OmniAb can attract partners and diversify exposure, but they require ongoing investment and commercial uptake to deliver value.
Extensive Partnership Exposure
A wide partner base spreads risk across programmes and indications, yet regulatory delays or clinical failures at partners can still materially affect results.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
